Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quad-dm1
- Development stage
- Unknown
- Lead developer
- Wake Forest University School of Medicine
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intracranial, Intravenous
01
Overview
QUAD-DM1 is a multivalent drug conjugate designed to target four receptors frequently overexpressed in glioblastoma and various brain metastases: EphA2, EphA3, EphB2, and interleukin 13 receptor alpha 2 (IL-13RA2). The therapeutic consists of a multivalent ligand (QUAD) conjugated to DM1 (mertansine), a potent microtubule-disrupting agent. By targeting multiple receptors simultaneously, QUAD-DM1 aims to overcome tumor heterogeneity and increase the precision of payload delivery. Developed by researchers at Wake Forest School of Medicine, the agent has shown significant efficacy in preclinical models of glioblastoma, triple-negative breast cancer (TNBC) brain metastasis, lung cancer, and melanoma. It has also undergone dose-limiting toxicity and efficacy studies in canine models of spontaneous glioma, supporting its transition into human clinical trials.
- Other names
- QUAD cytotoxin
02
Targets
EPHA3 (Ephrin Receptor A3)EPHB2 (Ephrin type-B receptor 2)TUBB (Tubulin (alpha and beta subunits))IL13RA2 (Interleukin-13 receptor subunit alpha 2)EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on quad-dm1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quad-dm1.